China First Domestic COVID-19 Antibody Therapy Moves Towards Green Light
Strong Overseas Efficacy Data
Brii’s antibody combo therapy nears approval in China, based on data from a late-stage study conducted outside the country.
You may also be interested in...
Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral.
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
The world’s second-largest economy is fast moving away from reforms and open to a "dual circulation" model, focusing on domestic market consumption while reducing export-driven production. Executives and investors shared views at a conference on whether multinational pharma firms are still welcome in China and what opportunities may lie in the drastic policy shift.